Arrowhead Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARWR research report →
Range $74 – $126
Price Chart
About the company
Arrowhead Pharmaceuticals, Inc. , founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology.
- CEO
- Christopher R. Anzalone
- IPO
- 1993
- Employees
- 1,059
- HQ
- Pasadena, CA, US
AI snapshot
Six angles, distilled from the data.
ARWR remains in a deep corrective regime after a long run from its 52-week high of 95.49 toward the lower end of the range at 37.06. The shares are still well below the 200-day average of 71.09, which keeps the longer-term trend under pressure despite recent stabilization.
Street sentiment stays constructive, with a Buy consensus and a 111.2 average target versus the current share price. Recent calls have been mostly reiterated rather than upgraded, while Stifel trimmed its target to 96 after the Tryngolza print, showing confidence but more caution on near-term execution.
The earnings backdrop is mixed: ARWR has beaten 4 of the last 8 quarters, but the latest print missed badly at -3.04 EPS versus -1.59 expected. Next-year EPS estimates are still negative at -4.978, so shareholders should watch for pipeline progress and any improvement in loss trajectory.
Recent insider activity leans negative on discretionary trades, with eight sales and no open-market buys. The award and gift entries are routine compensation noise, but the cluster of director and executive selling, including the CFO and CMO, leaves the near-term signal tilted toward distribution rather than accumulation.
Profitability remains weak, with a -1.57 operating margin and -1.61 net margin, even though gross margin is an exceptional 99.6%. Revenue growth is still negative at -85.3% year over year, and free cash flow was -259.954 million, so the story still depends on pipeline conversion rather than current earnings power.
ARWR trades like a high-beta biotech name, with a 1.368 beta and a valuation that still reflects pipeline optionality more than current fundamentals. The setup favors investors who want exposure to late-stage RNAi assets, but the stock remains expensive relative to its negative earnings base.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.85B
- P/E
- -8.41
- Fwd P/E
- 9.99
- PEG
- -0.01
- P/S
- 13.42
- P/B
- 120.45
- EV/EBITDA
- -11.57
- Div Yield
- 0.00%
- Gross Margin
- 99.60%
- Op Margin
- -156.86%
- Net Margin
- -160.64%
- ROE
- -170.58%
- ROIC
- -47.58%
Latest fiscal year · YoY change
- Revenue
- $450.82M-45.6%
- Gross Profit
- $449.02M-45.9%
- Op Income
- $-707,171,000
- Net Income
- $-724,206,000-44302.6%
- EPS
- $-5.11-41785.2%
- OCF Growth
- -251.5%
- FCF Growth
- -281.0%
- 52W High
- $95.49
- 52W Low
- $37.43
- 50D MA
- $60.07
- 200D MA
- $70.54
- Beta
- 1.37
- RSI (14)
- 22
- Avg Volume
- 2.04M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Arrowhead said REDEMPLO’s FCS launch is gaining traction while the company prepares for a second-quarter 2027 sHTG launch backed by strong SHASTA data, a broader pipeline, and a cleaner balance sheet.· November 12, 2026
- REDEMPLO FCS launch showed accelerating demand: 950 new-to-brand prescriptions as of Sept. 30, up 63% QoQ, with more than 1,250 cumulative NBRx and over 860 prescribers recently.
- Management is targeting a potential U.S. sHTG launch in Q2 2027, with the sNDA filed on Nov. 2 and FDA acceptance into the STAR pilot program.
- SHASTA-3 and SHASTA-4 met primary and all prespecified secondary endpoints; median triglyceride reductions were 79% and 81% at month 12, and cumulative acute pancreatitis events were reduced 78% versus placebo.
- The company highlighted expanding access: more than 160 million U.S. lives now have REDEMPLO formulary coverage, while payer conversion remains a bottleneck.
- Arrowhead ended the year with nearly $1.2 billion in cash and investments and refinanced debt at a much lower cost, extending maturity to 2031 with no scheduled principal amortization before then.
Fiscal 2026 revenue was $450.8 million, down from $829.4 million in fiscal 2025. Net loss attributable to Arrowhead was $724.2 million, or $5.11 per share, versus a net loss of $1.6 million, or $0.01 per share, in fiscal 2025. The year-over-year comparison was affected by $829 million of collaboration revenue recognized in fiscal 2025 and a one-time $215 million priority review voucher expense in fiscal 2026. Product revenue from REDEMPLO was approximately $6.6 million. Operating expenses were approximately $1.16 billion versus $731 million last year; excluding the voucher expense, operating expenses were approximately $943 million. Cash and investments were nearly $1.2 billion at Sept. 30, 2026. Management did not provide formal quarterly or full-year financial guidance, but said it expects a potential U.S. sHTG launch in the second calendar quarter of 2027, subject to FDA approval.
Chris Anzalone framed the year as a transition from scientific promise to commercial execution, saying Arrowhead is building a real business around REDEMPLO while also expanding the platform into new tissues and targets. He was notably optimistic about the sHTG opportunity, saying the company believes it has a differentiated medicine, a large unmet-need market, and a commercial organization being built to support it. His tone was confident and ambitious, but he repeatedly emphasized that the company must prove it can convert prescriptions into paid access and ultimately profitable growth.
Dan Apel focused on the year’s financial drivers and the strengthened balance sheet. He said fiscal 2026 revenue was $450.8 million and net loss was $724.2 million, with the comparison affected by $829 million of collaboration revenue in the prior year and a $215 million priority review voucher expense this year; excluding that expense, net loss would have been approximately $509 million. He highlighted that cash and investments were nearly $1.2 billion, that the PRV could potentially be sold at market values he cited at roughly $180 million to $220 million, and that the Sixth Street refinancing cut borrowing costs from 15% to SOFR plus 5.5%, extended maturity to November 2031, and removed required cash sweeps and principal amortization before maturity.
Analysts pressed management on whether weak early uptake at Ionis signals a tougher sHTG market. Management said the issue is more likely execution-specific than market-specific and argued Arrowhead can benefit from being a second entrant, with more early payer engagement and better preparation. They also clarified that REDEMPLO launch success will be judged by prescriptions, prescriber breadth, and coverage, not just early revenue, and said it is too early to provide formal guidance because the label and payer dynamics are not yet known.
The call outlined multiple visible growth drivers: a strong FCS launch, a potential sHTG launch in Q2 2027, and a pipeline that is producing new clinical validation in cardiometabolic disease and CNS. Management cited deep triglyceride lowering, a 78% reduction in acute pancreatitis events, expanding payer coverage, and a much stronger financial position after the refinancing. They also expressed confidence that the company can leverage its commercial infrastructure across multiple programs and markets.
Management acknowledged that REDEMPLO still faces a conversion bottleneck between prescriptions and paid shipments, and that broader sHTG penetration will take time as payer policies evolve. They also said it is too early to provide launch guidance because the label and reimbursement landscape are still uncertain. On the pipeline, some programs still face important development and dose-selection questions, including ARO-DIMER-PA safety at higher doses and the still-early nature of the CNS and obesity programs.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.9%
- Shares Outstanding
- 141.37M
- Float Shares
- 122.91M
of shares held by institutions
525 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ARWR, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Jan 31, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 15.29M | ▼ 742.75K |
| Blackrock, Inc. | 15.14M | ▲ 310.29K |
| Avoro Capital Advisors LLC | 11.00M | ▼ 355.56K |
| Fmr LLC | 9.36M | ▲ 1.32M |
| Vanguard Portfolio Management LLC | 6.21M | ▼ 140.40K |
| State Street Corp | 6.12M | ▲ 427.63K |
| Vanguard Capital Management LLC | 6.12M | ▲ 7.77K |
| Vestal Point Capital, LP | 4.82M | ▲ 3.24M |
| Norges Bank | 3.90M | ▲ 3.90M |
| Invesco Ltd. | 3.83M | ▼ 58.83K |
| Geode Capital Management, LLC | 3.46M | ▼ 72.14K |
| Fred Alger Management, LLC | 3.26M | ▼ 46.08K |
Held by 583 ETFs
Biggest fund positions in ARWR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 18, 26 | OLUKOTUN ADEOYE Y | sell | 2,000 |
| Aug 18, 26 | PERRY MICHAEL S | sell | 11,600 |
| Jun 15, 26 | Cohen Matthew Gregory | other | 11,882 |
| Jun 15, 26 | Cohen Matthew Gregory | other | 0 |
| May 12, 26 | Lu Hongbo | sell | 2,970 |
| Apr 22, 26 | Apel Daniel Joseph | sell | 3,208 |
| Apr 22, 26 | Apel Daniel Joseph | sell | 1,157 |
| Apr 22, 26 | Apel Daniel Joseph | sell | 8,730 |
| Apr 23, 26 | Hamilton James C | sell | 10,000 |
| Mar 5, 26 | Hamilton James C | sell | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARWR coverage
Recent articles, reports, and earnings notes.

Arrowhead Pharmaceuticals (ARWR): REDEMPLO and sHTG Upside
Arrowhead is transitioning from a development-stage RNAi story to an early commercial biotech, with REDEMPLO traction and strong Phase 3 data for plozasiran driving the thesis. The stock still carries meaningful clinical and cash-burn risk, but the pipeline breadth and sHTG opportunity support a Buy view.

City Therapeutics IPO: What Investors Need to Know
City Therapeutics Inc. (NASDAQ: CTY) is expected to list on October 16, 2026, on the NASDAQ, with the IPO priced at $18.00 per share for 11,111,111 shares. The company has not disclosed a public price range in the calendar data, but the deal was upsized, which points to solid demand. Bull case: early clinical RNAi data and a deep platform story. Bear case: it is still pre-commercial, loss-making, and years away from proving the pipeline.

ADARx Pharmaceuticals IPO Preview: RNA Pipeline Meets Cash Burn
ADARx Pharmaceuticals is expected to list on NASDAQ on 2026-09-25, with shares priced in a $15.00 to $17.00 range. The company is offering 21,875,000 shares and has disclosed an implied market cap of $427,656,250. The setup favors investors who want late-stage RNA exposure, but the key watch item is whether the market gives credit to the pipeline before more clinical data arrives.
Want a deeper read on ARWR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Arrowhead Pharmaceuticals Eyes $3 Billion REDEMPLO Opportunity as FDA Review Looms
marketbeat.com · Nov 20
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
businesswire.com · Nov 17
94,000 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR Bought by ACT Capital Partners L.P.
defenseworld.net · Nov 15
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
marketbeat.com · Nov 12
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
businesswire.com · Nov 12
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
businesswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice